Therapy Areas: Devices
Asieris Pharmaceuticals doses first European patient in APL-1702, Cevira Phase III clinical trial
22 June 2021 -

Asieris Pharmaceuticals, a global pharma company, announced on Tuesday that it has dosed its first patient in Europe in its multinational, multicentre, Phase III clinical trial (APRICITY) of its photodynamic drug-device combination product APL-1702, Cevira.

The product has been developed as a novel non-surgical treatment of cervical high-grade squamous intraepithelial lesions (HSIL), a pre-cancerous condition caused by a persistent HPV infection.

The study is a multinational, multicentre, randomised, double blind, prospective, placebo-controlled phase III clinical trial to assess the efficacy and safety of APL-1702, Cevira in HSIL. It is an integrated combination of drug and device. Presently, the trial is open for recruitment.

Login
Username:

Password: